During the Trading Day
| 3.43 |  -0.01 / -0.29% |
Data as of 4:00pm ET | Day’s Change | |
| 3.43 |  0.00 / 0.00% |
| Volume: 4.9K |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $277.1M |
Company Description
Curis, Inc. is a drug development company, which is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. It conducts research programs both internally and through strategic collaborations. It operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The company was founded in February 2000 and is headquartered in Lexington, MA.
Employees
Shareholders
| Other institutional | 32.46% |
| Mutual fund holders | 18.98% |
| Individual stakeholders | 10.53% |
Top Executives
| Ali Fattaey, PhD | President & Chief Operating Officer |
| Daniel R. Passeri | Chief Executive Officer & Director |
| Michael P. Gray, MBA, CPA | Secretary, Chief Financial & Business Officer |
| Maurizio Voi, MD | Chief Medical & Development Officer |
| Mark W. Noel | VP-Technology Management & Intellectual Property |
.
